Approximately 25 CONCLUSIONS: IBS-D with increased BA excretion or synthesis is associated with signifi cant pathophysiological changes relative to patients with normal BA profi le. BA diarrhea is identifi ed more effectively with total fecal BA than with serum C4.
INTRODUCTION
Approximately 25 % of patients with irritable bowel syndromediarrhea (IBS-D) have increased total fecal bile acids (BA) or other evidence of bile acid malabsorption, most readily demonstrated using 75 SeHCAT retention test ( 1 ) . Although therapeutic trial with BA sequestrants is still the predominant method to make a tentative diagnosis of BA diarrhea (BAD), two serological tests may soon be widely available to facilitate the identifi cation of BAD. Serum 7 α -OH-4-cholesten-3-one (C4) is a surrogate for hepatic BA synthesis rate; serum C4 is elevated in patients with BA malabsorption ( 2 ) and in a subset of patients with IBS-D ( 3 ) . A second blood test ( 4 ) is based on the seminal documentation by Walters et al. ( 5 ) of a molecular mechanism (defi ciency of fi broblast growth factor 19 (FGF19) secretion by ileal enterocytes) in patients with BAD. Th is was confi rmed by other groups ( 3, 6 ) . In a recent comparison between serum FGF19 and 75 SeH-CAT retention test results, receiver operating characteristic curve analysis showed that FGF19 ≤ 145 pg / ml could predict 75 SeHCAT values < 10 % or < 5 % in 58 % (95 % confi dence interval 42 -72) and 67 % (95 % confi dence interval 38 -87) of patients; moreover, 15 of 16 patients with serum FGF19 ≤ 145 pg / ml responded to BA sequestrants ( 4 ) . Two BA-related genes, klotho B ( KLB ) and fi broblast growth factor receptor 4 ( FGFR4 ), are associated with accelerated small intestinal or colonic transit (CT) in IBS-D ( 7, 8 ) .
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It is unclear whether BAD alters the pathophysiology in patients presenting with the symptom phenotype of IBS-D. Such insights may enhance the therapeutic approach to IBS-D, with greater emphasis on the specifi c treatment of the BAD contributing to the phenotype of IBS-D ( 9 ) .
Our hypothesis was that increased fecal BA or increased serum C4 are associated with signifi cant diff erences in quantitative traits such as colonic sensorimotor and intestinal or colonic permeability compared with patients with normal BA excretion and synthesis. Th e aims of the study were: (i) to compare phenotype, colonic motor or sensory functions, and permeability in IBS-D patients having increased fecal BA or increased serum C4 with patients having normal BA excretion and synthesis; and (ii) to explore associations of genetic variations in KLB and FGFR4 in these two subgroups of IBS-D.
METHODS
Study design
We appraised bowel functions, total fecal BA, colonic motility, sensation and permeability, and BA synthesis and excretion in 64 patients with IBS-D (by Rome III criteria) in order to identify the patients with IBS-D who had evidence suggestive of BAD, based on increased fecal total BA excretion or increased BA synthesis.
Patient selection
Patients were recruited by public advertisement or by invitation to participate from a database of ~ 1,200 patients with IBS living in communities within ~ 120 miles of Mayo Clinic in Rochester, MN.
Characterization of bowel function
A validated diary-based questionnaire was used to characterize IBS symptoms and particularly bowel functions ( 10 ) . Participants also completed the Hospital Anxiety and Depression Inventory ( 11 ) .
Measurements of quantitative traits
All participants underwent measurement of quantitative traits by methods that have been previously used extensively and validated in our laboratory. Th ese are described briefl y here:
(i) Fasting serum C4 (sampled in the morning) measured by high-performance liquid chromatography / tandem mass spectrometry ( 12 ) . Serum C4 is a validated method for BAM. In headto-head comparisons with the 75 SeHCAT retention test, increased serum C4 had a sensitivity of 90 % and a specifi city of 79 % in diagnosing BAM ( 13 ) where shorter retention half-time of 75 SeHCAT is associated with increased level of C4, and it had 98 % negative predictive value and 74 % positive predictive value for diagnosis of BAM ( 14 ) .
Based on the method adapted from G ä lman et al. ( 15 ) and using high-performance liquid chromatography / tandem mass spectrometry, we used serum C4 to screen for high BA synthesis ( 12 ) . Th e lowest limit of detection of serum C4 using this assay is 0.04 ng / ml ( 12 ).
(ii) Fasting serum FGF19 measured by a commercial enzymelinked immunosorbent assay (FGF19 Quantikine Enzyme-Linked Immunosorbent Assay Kit; R & D Systems, Minneapolis, MN) as in prior studies ( 3, 6 ) .
As there are diurnal variations in measurements of C4 ( 16 ) and FGF19 ( 17 ) , these measurements were conducted on fasting blood samples.
(iii) Total and main fecal BA excretion (per 48 h on 100 g fat diet, measured by high-performance liquid chromatography / tandem mass spectrometry) ( 3, 18, 19 ) . Th is assay was adapted from a method used with serum samples ( 20 ) . We have previously documented the analysis and analytical performance ( 18 ); the lower limit of quantitation of each of the individual measured BAs (cholic acid, deoxycholic acid, chenodeoxycholic acid, and lithocholic acid) is 0.06 μ mol (in methanol extract).
(iv) Fecal fat measured by nuclear magnetic resonance spectrometry at Mayo Clinic ' s Department of Laboratory Medicine and Pathology.
(v) Overall CT by scintigraphy (geometric center (GC)) at 24 and 48 h ( 21 ). We have extensively validated the measurement of CT by scintigraphy including both accelerated and delayed CT, inter-and intra-individual coeffi cient of variation, eff ect sizes demonstrable and statistical power based on defi ned sample sizes, and responsiveness of the primary end points to pharmacological eff ects of medications including correct prediction of effi cacy of those medications in subsequent phase IIB or III clinical trials ( 22 -25 ) .
(vi) Intestinal and colonic permeability: we administered 1 g lactulose and 0.2 g mannitol in 240 ml water to study permeability ( 26 ) . We had previously identifi ed increased small bowel permeability in IBS-D compared with healthy controls ( 27 ) . Th e 0 -2 h urine refl ects most closely small intestinal permeability, and the 8 -24 h urine refl ects colonic permeability; the validated highperformance liquid chromatography / tandem mass spectrometric method was used ( 26 ) . Participants were all nonsmokers and had not ingested during the 2-week period before these measurements nonsteroidal anti-infl ammatory drugs or other drugs that could interfere with the interpretation of the results. We have previously ( 27, 28 ) demonstrated that, in the context of non-infl ammatory, nonulcerated bowel disorders like IBS, there is little lactulose absorbed and excreted ( ~ 2 % of the mass administered orally) compared with mannitol ( ~ 25 % of oral load). Th erefore, the primary end point used to assess permeability was urine mannitol excretion.
In addition, 47 of the 64 patients with IBS-D also consented to undergo measurement of colonic sensation and postprandial tone by barostat; all colonic motility and sensation data garnered were included in the analysis ( 29, 30 ) .
Genotyping of venous blood DNA
DNA was extracted from venous blood, and candidate genotype analysis was conducted using established PCR-based methods: rs17618244 ( KLB ) and rs351855 ( FGFR4 ). Th ese candidate genes were selected based on prior studies from our group documenting relationship between BA-related genes and small intestinal or colonic transit ( 8, 7 ) . Th e methods have been published elsewhere ( 7 ) . However, there is evidence from exome DNA sequence study ( 31 ) that other variants in KLB (rs1015450, downstream) and FGFR4 rs434434 (intronic), rs1966265, and rs351855 (nonsynonymous)) were associated with CT ( FGFR4 rs1966265) and fecal bile acids ( KLB rs1015450). Th ere is also evidence that subgroups of patients, based on CT and fecal BA excretion, were significantly associated with all three FGFR4 single-nucleotide variants ( 31 ) . In addition, an analysis of a 633-person cohort showed that FGFR4 rs434434 was associated with symptom phenotype ( 31 ) , and FGFR4 rs1966265 and rs351855 modulate KLB rs1768244 association with 24-h CT in IBS-D ( 7 ). Th erefore, we conducted further genotyping of these polymorphisms to assess the relationships with IBS-D and BAD. We did not assess the association with other genes involved in the enterohepatic circulation for two reasons: fi rst, the other genes were not previously shown to be associated with CT ( 7 ); and second, the limited number of patients with these quantitative measurements adequately supported the study of three main genes of interest. For all gene variants tested, we have previously reported ( 7, 31 ) that all were in Hardy -Weinberg equilibrium in healthy participants from the same region (with similar ethnic and racial distribution to that of the cohort reported here).
Statistical power and sample size
Th e sample size was based on the previously observed results of the primary end points in volunteers in our lab (data in Table 1 show mean ± s.d.). Th e estimated eff ect sizes are based on a twosample t -test with the number per group shown in Table 1 (i.e., 30 vs. 30 or 20 vs. 40, which were the predicted proportions of numbers of patients with evidence of increased BA excretion or synthesis). Th e eff ect size is the diff erence in group means as a percentage of the overall mean.
Statistical analysis
Bowel functions, individual fecal BA, CT, colonic compliance, postprandial tone and sensation, and intestinal permeability were compared in IBS-D subgroups identifi ed by fecal BA excretion > 2,337 m M per 48 h or by serum C4 > 47.1 ng / ml based on 90th percentile of healthy volunteers studied in our laboratory (45 and 163 subjects, respectively) ( 3, 12 ) . Th e 90th percentile was used to defi ne the upper limit of normal range, consistent with the observation that a normal distribution requires sampling of 500 normal people ( 32 ) . We used Fisher ' s exact test to assess associations of subgroups based on BA biology and the two BA-related genes (2 degree of freedom general genetic model). Biological samples were missing in 10 participants; therefore, the analysis was based on all 54 with complete data for serum C4, fecal BA excretion, and all the quantitative traits. Th e associations between fecal BA excretion or serum C4 and CT (at 48 h and ascending colon emptying T 1 / 2 ) were assessed using Spearman ' s correlation coeffi cients. Table 2 summarizes number of bowel movements, stool consistency, CT (GC48 h), small intestinal permeability, fecal fat, serum FGF19 and C4, and total fecal BA in the 64 patients with IBS-D. Data for the 54 who had all blood and stool measurements available are also presented in Table 2 and illustrate that there were no appreciable diff erences between the groups.
RESULTS
Characterization of phenotype and pathophysiology
Comparison of IBS-D subgroups based on fecal total BA excretion
In the group (19 / 54) with fecal BA > 2,337 m M per 48 h (90 % ile of normal value), there were signifi cantly greater body mass index, fecal fat, percent chenodeoxycholic acid (CDCA) and cholic acid in stool, and intestinal permeability ( Table 3 ) . Th ere was a reciprocal lowering of stool lithocholic acid percentage. In the group with fecal BA, there were borderline accelerations of CT at 24 and 48 h (both P = 0.13) and postprandial colonic tone in the fi rst 30 min aft er meal ( P = 0.07), but no diff erences in postprandial colonic phasic motility index or colonic sensation. Th e numerically different serum C4 levels in the two groups based on total fecal BA excretion were not statistically signifi cant ( P = 0.228).
Th ere was a signifi cant overall correlation between total fecal BA excretion and CT at 48 h ( r s = 0.32, P = 0.0132). Th is was predominantly observed in patients with total fecal BA excretion within Mannitol excretion based on data acquired in our lab in health and IBS-D ( 27 ) .
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the normal range ( Figure 1 ). Th e overall correlation between fasting serum C4 and CT at 48 h ( Figure 2 ) was borderline ( r s = 0.232, P = 0.082); the association of serum C4 and CT appeared to be associated predominantly with ascending colon emptying T 1 / 2 ( r s = − 0.277, P = 0.0791) in patients with serum C4 within the normal range ( < 47.1 ng / ml).
Comparison of IBS-D subgroups based on serum C4
In the subgroup (13 / 54) with serum C4 > 47.1 ng / ml (90 % ile of normal value), there were increased total fecal BA excretion and percentage of deoxycholic acid (DCA) in stool ( Table 4 ) . Th ere was borderline increase in colonic mucosal permeability but no signifi cant diff erences in CT, colonic tone, phasic motility, or sensation.
Comparison of IBS-D subgroups based on elevated fecal BA excretion and serum C4
In the subgroup (5 / 54) with fecal BA > 2,337 m M per 48 h and serum C4 > 47.1 ng / ml, there were no signifi cant diff erences in the quantitative measurements compared with the group of patients with neither parameter elevated (27 / 54), except for the expected higher serum C4 and total fecal BA excretion ( Table 4 ) .
Relationship of BA-related genes and subgroups of IBS-D based on total fecal BA or serum C4
Rs17618244 or rs1015450 ( KLB ), and rs351855, rs 1966265, or rs434434 ( FGFR4 ) were not signifi cantly associated with subgroups based on increased fecal total BA ( Table 5 ) ; however, gene variants in KLB (rs1015450 ( P = 0.06)) and FGFR4 (rs1966265 ( P = 0.09)) were borderline signifi cantly associated with the subgroup defi ned by elevated serum C4 level.
DISCUSSION
Overall differences in the pathophysiological features associated with IBS-D subgroups
Our study shows that there are some quantitative diff erences in the pathophysiological features associated with IBS-D in patients with increased fecal BA excretion or increased BA synthesis. Th e proportion of IBS-D patients in whom there was evidence of increased BA excretion or synthesis in the current, prospectively studied patient cohort is consistent with the 25 -35 % reported in the literature or in prior studies ( 1 ), and with other recent papers in the literature ( 33, 34 ) . In a prior study ( 35 ) , the increased colonic exposure to bile acids was also shown to infl uence bowel function and CT time (signifi cant only in the left colon) in patients with IBS. Th e same authors observed response to open-label treatment with the BA sequestrant, colestipol, supporting the role of bile acids in the bowel dysfunction in these patients ( 35 ) . In assessing the pathophysiological associations of the two approaches to identifying BA component to the diarrhea in IBS-D patients, this study shows that those with fecal BA > 2,337 m M per 48 h had higher fecal fat, percent CDCA in feces, and intestinal permeability, and had borderline increased CT ( P = 0.13), suggesting that steatorrhea, secretion (by the increased proportion of the secretory BA, CDCA, and increased permeability) and, possibly, accelerated CT may be inferred by the fi nding of increased fecal total BA.
We observed increased proportion of the secretory bile acid, chenodeoxycholic acid, and the nonsecretory lithocholic and cholic acids in the patients with increased fecal BA excretion. Th ere was a nonsignifi cant mean diff erence of 0.7 GC units in CT at 24 h. Th e facts that BA malabsorption is so prevalent in patients with clinical symptoms of IBS-D and that other symptom and pathophysiological traits were not diff erent in the two groups suggest that BAD should be excluded in patients presenting with symptoms of IBS-D, especially if there is an insuffi cient response to fi rst-line therapy, such as with loperamide.
Colonic transit
Overall, these patients with IBS-D had acceleration in CT ( 36 ) with colonic geometric center at 24 and 48 h of 2.98 ± 0.2 (s.e.m.) and 4.26 ± 0.13 respectively; normal laboratory values for CT at 24 and 48 h in 220 healthy volunteers reported from our laboratory were 2.4 ± 0.06 and 3.6 ± 0.08, respectively ( 37 ) . Th e current 
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In contrast, in patients with increased BA synthesis, there was no signifi cant correlation with CT, suggesting another mechanism contributes to their rapid CT. Th ese data are also consistent with our recent fi nding on principal components analysis of patients with the symptom phenotype of IBS-D that showed at least two identifi able subgroups ( 31 ): fi rst, a fast CT group of patients with modest increase in fecal BA and normal serum C4 (median 21.1 (interquartile range 12.9, 29.0)) and markedly accelerated transit at 24 h (4.57 (interquartile range 3.10, 4.79)) in whom the increased fecal BA may represent " spillage " of BA; second, increased BA synthesis diarrhea patients with increased serum C4 (median 68.0 (33.1, 75.2)) in whom CT is modestly accelerated (median 2.41 (interquartile range 1.62, 3.54)). Th e relationship between fecal BA and CT is consistent with documented eff ects of intraluminal administration of 1 m M CDCA and induction of high-amplitude propagated pressure waves in the colon ( 39 ) , and the administration of 500 to 1,000 mg (1.2 -2.4 m M ) sodium chenodeoxycholate in a delayed-release capsule that induced bowel function and accelerated CT in health and IBS-constipation ( 6,38 ). analysis shows only borderline signifi cance ( P = 0.13) for the comparison in CT between high compared with normal fecal BA excretion groups, despite 0.7 GC unit diff erence in mean colonic GC at 24 h; this may refl ect insuffi cient power with the sample size studied. Table 1 predicted that a comparison of 20 vs. 40 patients (rather than 15 vs. 39 patients) would be suffi cient to demonstrate an eff ect size of 20 % in the colonic GC at 24 h. Th e observed diff erence in the means of colonic GC24 in the two groups was 24 % (0.65 / 2.75), suggesting that the lack of diff erence in CT in the two groups was because of the larger observed s.d. with reduced statistical power. Th e statistically signifi cant correlations between overall CT and fecal BA excretion or serum C4 suggest that colonic BA content is associated with CT, consistent with prior studies showing that ileocolonic delivery of chenodeoxycholate accelerated CT in healthy controls ( 6 ) and patients with IBS-constipation ( 38 ) , and the retardation of CT with the BA sequestrant colesevelam in IBS-D ( 6 ) . Th e eff ect of BA on CT appears to be saturable as there was a positive correlation of fecal bile excretion in the normal range with CT and an inverse correlation between serum C4 and ascending colon emptying time. [2] Note that normal laboratory values for colonic transit at 24 and 48 h in 220 healthy volunteers were 2.4 ± 0.06 (s.e.m.) and 3.6 ± 0.08, respectively. * P < 0.05; ** P < 0.01; 
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Bile Acid Diarrhea in IBS with both increased serum C4 and total fecal BA excretion was certainly not large enough to appraise whether the combination of increased BA synthesis and excretion actually aff ected the phenotype of IBS-D. Studies in larger numbers of patients would be required to appraise the impact of both increased serum C4 and total fecal BA excretion. Recent data suggest that these prokinetic eff ects may be mediated through the GPBAR1 receptor ( 40 ) . Th e presence of excess BA in feces was associated with elevated fecal fat, percentage of secretory BA in stool, increased intestinal permeability, and borderline increased CT.
Steatorrhea
Th e cause of steatorrhea in patients with increased fecal BA excretion may refl ect lower critical micellar concentration because of relative BA defi ciency due to chronic loss of BA in stool. Th ough pancreatic exocrine insuffi ciency might be considered, the fecal fat excretion in the overall IBS-D group is still consistent with the range reported in experimental osmotic diarrhea, that is, up to ~ 23.5 g / day ( 41 ) . Nevertheless, fecal fat was signifi cantly higher in patients with high fecal BA excretion than those with normal fecal BA excretion, suggesting that these patients may, in fact, develop a relative BA defi ciency causing low-grade steatorrhea. It is conceivable that these patients may benefi t from dietary fat restriction or supplementation of a nonsecretory BA such as ursodeoxycholic acid (UDCA). Th is may benefi t patients by enhancing the formation of micelles to facilitate fat absorption in the small bowel or to attenuate colonic epithelial secretion ( 42 ) . It is relevant to note that the concentrations at which UDCA has its antisecretory actions (50 μ M -1 m M ) are not achievable normally in vivo . Th us, our study shows that only ~ 3 % of the average 2,500 m M excreted BA is in the form of UDCA, and it is conceivable that the levels observed in feces represent, at least in part, the eff ects of bacterial β -epimerization of CDCA reaching the colon; hence, the concentration of UDCA reaching the colon is likely to be lower than 50 m M . Th is is consistent with the prior report by De Kok et al. ( 43 ) . Th erapeutic supplementation of UDCA in healthy volunteers (e.g., 300 and 600 mg / day) signifi cantly increased the concentrations in the colonic lumen and serum ( 44, 45 ) . In fact, as UDCA is bacterially metabolized to lithocholic acid in the colon (which does not have antisecretory action, but is the main metabolite detected in human studies of UDCA supplementation) ( 44 ) , it is likely that the main eff ect of supplementation of UDCA will be to enhance fat absorption. Th e antisecretory eff ects of UDCA could be achieved by supplementation of 6 α -MUDCA, a 6-methylated derivative of UDCA that is completely resistant to bacterial dehydroxylation ( 46 ) , as demonstrated in mice in vivo ( 42 ) .
Increased intestinal permeability
Th e reason for increased small intestinal permeability is not explored in the current studies. Our hypothesis is that increased colonic BA (and associated increased C4 and hepatocyte BA synthesis) was associated with increased concentrations of BA in the small bowel. It has been demonstrated that hydrophobic BA increased small intestinal permeability, in part through nicotinic
We assessed whether having both increased serum C4 and total fecal BA excretion would result in diff erences in the quantitative traits measured. However, the sample size of only fi ve patients 
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cholinergic mechanisms or changes in small intestinal brush border membrane fl uidity and fragility ( 47 -51 ) .
In patients with serum C4 > 47.1 ng / ml, there are increased total fecal BA excretion and borderline increased colonic permeability that may refl ect higher fl uid and electrolyte secretions and contribute to the loose stool consistency of patients with IBS-D.
Screening for BA diarrhea in patients with diarrhea-predominant IBS
BAD may be more eff ectively assessed with total fecal BA than with serum C4. Th us, our study identifi ed increased fecal BA excretion in 19 / 54 patients with IBS-D and increased serum C4 in 13 / 54 of those patients. Th e group of patients with increased serum C4 had elevated fecal BA excretion. In contrast, patients with increased fecal BA excretion did not necessarily have increased serum C4; these patients had a nonstatistically increased serum FGF19 level, suggesting that the increased intraluminal BA (that ultimately caused increased total fecal BA excretion) stimulated ileal production of the hormone, FGF19 that reduced hepatocyte synthesis of C4, a surrogate of BA synthesis.
Genetic variation and control of BA homeostasis
Th e study explored genetic variation in KLB and FGFR4 , and borderline univariate associations were identifi ed between KLB (rs1015450 ( P = 0.06)) and FGFR4 (rs1966265 ( P = 0.09)) and the subgroup of IBS-D patients with elevated fasting serum C4, but not with increased fecal BA excretion. We had previously observed signifi cant associations of KLB rs1015450 ( 31 ) and FGFR4 rs1966265 ( 3 ) with fecal BA excretion. Th e KLB rs1015450 is intronic and its functional significance has not yet been demonstrated. On the other hand, FGFR4 rs1966265 results in a valine to isoleucine change at position 10, and this single-nucleotide polymorphism appears to be functionally relevant, in view of the recent association with alveolar function ( 51 ) .
Th e current data on associations of these single-nucleotide polymorphisms with BA homeostasis are hypothesis generating; if confi rmed, this would be consistent with the known role of KLB and FGFR4 proteins in the feedback inhibition of hepatocyte BA synthesis. Th us, FGF19, secreted by enterocytes and reaching the liver through the portal venous return, normally binds to the FGFR4 receptor with interaction with KLB protein, and results in the inhibition of CYP7A1 in the BA synthesis pathway. Defi ciencies of KLB or FGFR4 result in reduced inhibition of CYP7A1 and, hence, greater BA synthesis. Th is is indirectly refl ected in the higher fasting serum C4 measurements. Th ese genetic associations are of potential biological relevance, given the fact that the observations were based on 13 patients with elevated serum C4 and 41 with normal C4 measurements.
Strengths and limitations
Th e strengths of this study include the in-depth analysis of the phenotype of IBS-D and the use of two validated markers to identify the contribution of BAs (refl ecting predominantly synthesis and excretion of the bile acids) to the overall phenotype. Th is is the fi rst documentation of BA dysregulation and the associated quantitative manifestations in IBS-D.
A limitation of our study is that only 54 of the 64 patients with IBS-D were willing to participate in the 48-h fecal collections; regrettably, noninvasive 75 SeHCAT retention test based on imaging is not available to be used as an alternative in the United States. In addition, we conducted multiple comparisons to characterize the quantitative traits between health and IBS and between patients with high compared with normal BA excretion. Importantly, for each physiological trait examined (e.g., CT, intraluminally measured colonic motility, or permeability), we had prespecifi ed no more than two quantitative traits (e.g., CT at 24 and 48 h). Th e observed borderline associations with gene variants in KLB and FGFR4 provide the basis for further hypotheses-testing studies; if confi rmed in a larger sample of patients, these fi ndings may provide an alternative approach to screening patients for BAD and serve as complementary tests to measurements of serum C4 ( 12 ) and FGF19 ( 4 ), given the questions raised regarding the cost eff ectiveness of 75 SeHCAT retention test and the logistic diffi culties associated with 48-h stool collections ( 52 ) .
In conclusion, IBS-D with increased BA excretion or synthesis (relative to normal BA profi le) is associated with quantitative changes in fecal fat excretion, CT, and intestinal permeability, but there are no easily identifi able traits to distinguish the two groups. Given the high prevalence of BAD among patients with IBS-D (25 -33 % in the current cohort based on serum C4 and fecal BA excretion, respectively), there should be liberal screening for BAD in patients with IBS-D who do not respond to symptomatic treatment, such as with loperamide. Th e clinical relevance of fi nding BAD in IBS-D will be enhanced with future randomized, controlled studies that incorporate treatment, including sequestration of BA, or farnesoid X receptor agonists such as obeticholic acid ( 53 ) . Such studies will build on evidence from open-label studies with colestipol ( 35 ) or smaller mechanistic studies with colesevelam ( 6 ), and may usher in a more specifi c approach of treatment targeting the BAD in patients with IBS-D who have either increased fasting serum C4, reduced serum FGF19 ( 4 ), increased 48-h total fecal BA, or reduced 75 SeHCAT retention. Finally, our studies show that, in a setting where 75 SeHCAT retention test is not available, BAD is identifi ed more eff ectively with total fecal BA than with serum C4.
